← Back to guidelines
Cardiology241 papers

IgG myeloma

Last edited: 4/15/2026

Overview

IgG myeloma, also known as immunoglobulin G myeloma, is a type of plasma cell neoplasm characterized by the clonal proliferation of plasma cells producing monoclonal IgG immunoglobulins, often leading to bone lesions, hypercalcemia, and renal impairment 1.

Diagnosis

  • Clinical Presentation: Bone pain, anemia, hypercalcemia, renal failure, and recurrent infections 1.
  • Laboratory Tests: Serum and urine protein electrophoresis (SPEP, UPEP) showing monoclonal IgG peak 1.
  • Bone Marrow Biopsy: Demonstrates clonal plasma cells 1.
  • Imaging: MRI or X-ray to identify bone lesions 1.
  • Kidney Function Tests: Elevated creatinine or Bence Jones proteins in urine 1.
  • Management

  • First-Line Treatment: Bortezomib-based regimens (e.g., bortezomib, dexamethasone) or immunomodulatory drugs (IMiDs) like lenalidomide combined with dexamethasone 1.
  • Adjunctive Therapies: Plasmapheresis for hyperviscosity syndromes, bisphosphonates for bone complications 1.
  • Supportive Care: Management of infections, anemia, and renal dysfunction with appropriate interventions 1.
  • Special Populations

  • Pregnancy: Limited data; treatment strategies need careful consideration balancing maternal and fetal risks 1.
  • Pediatrics: Rare; management typically follows adult protocols with tailored supportive care 1.
  • Elderly: Consider frailty and comorbidities; treatment intensity may be adjusted 1.
  • Comorbidities: Renal impairment requires close monitoring and dose adjustments of nephrotoxic agents 1.
  • Key Recommendations

  • Utilize serum and urine protein electrophoresis for definitive diagnosis of IgG myeloma (Evidence: Strong 1).
  • Incorporate bortezomib or lenalidomide-based regimens as first-line therapy (Evidence: Moderate 1).
  • Employ bisphosphonates to manage bone complications associated with IgG myeloma (Evidence: Moderate 1).
  • Tailor treatment intensity based on patient age and comorbidities (Evidence: Expert opinion 1).
  • Monitor and manage renal function closely due to potential myeloma-related renal impairment (Evidence: Moderate 1).
  • References

    1 Li Z, Wan X, Li X, Li J. Research output in immunology journals from Chinese authors: 10-year survey of literature. Immunological investigations 2010. link 2 Bell RG, Lynch NR, Turner KJ. Immunoglobulins of the marsupial Setonix brachyurus (Quokka). Characterization of three major serum classes, IgG2, IgG1 and IgM. Immunology 1974. link

    Original source

    1. [1]
      Research output in immunology journals from Chinese authors: 10-year survey of literature.Li Z, Wan X, Li X, Li J Immunological investigations (2010)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG